Barclays PLC Raises Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Barclays PLC raised its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 145.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 79,740 shares of the company’s stock after buying an additional 47,239 shares during the period. Barclays PLC owned about 0.15% of Stoke Therapeutics worth $980,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lynx1 Capital Management LP increased its position in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after acquiring an additional 1,488,371 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after buying an additional 1,123,500 shares during the last quarter. Logos Global Management LP bought a new stake in Stoke Therapeutics during the second quarter valued at approximately $14,186,000. Marshall Wace LLP increased its holdings in Stoke Therapeutics by 550.1% during the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after buying an additional 982,451 shares during the last quarter. Finally, RTW Investments LP raised its position in Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares during the period.

Wall Street Analyst Weigh In

Several research firms have recently commented on STOK. Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. Chardan Capital assumed coverage on Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $21.29.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 13,945 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10. Following the sale, the insider now owns 47,332 shares of the company’s stock, valued at $604,902.96. This represents a 22.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the transaction, the chief executive officer now directly owns 61,885 shares of the company’s stock, valued at $803,886.15. The trade was a 9.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock valued at $809,421 in the last quarter. 11.30% of the stock is currently owned by insiders.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $8.68 on Wednesday. The firm has a market cap of $459.75 million, a price-to-earnings ratio of -4.13 and a beta of 0.95. The firm has a fifty day moving average price of $11.73 and a 200 day moving average price of $12.97. Stoke Therapeutics, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, research analysts predict that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.